miRNA-140过表达腺病毒载体的构建及鉴定-东南大学学报医学版

miRNA-140过表达腺病毒载体的构建及鉴定

单位：1. 南方医科大学附属深圳恒生医院口腔科, 广东深圳 518000;
2. 深圳市第二人民医院(深圳大学第一附属医院), 深圳市组织工程重点实验室, 广东深圳 518035

分类号：Q782

出版年·卷·期（页码）：2016·35·第一期（6-10）

摘要：

目的:构建稳定表达成熟miRNA-140腺病毒表达载体。方法:从人类基因组中扩增出带有酶切位点的miRNA-140目的基因,将目的基因连接到穿梭质粒pDC316-mCMV-EGFP,进一步将带有目的基因的穿梭质粒重组到骨架质粒AdEasy,并将重组质粒转染到AAV-293细胞中包装成腺病毒载体,经过二次扩增之后获得高滴度的腺病毒,并且检测其包装效率及感染滴度。最后,用目的腺病毒感染骨肉瘤细胞,通过荧光定量PCR方法检测miRNA-140表达情况。结果:酶切鉴定和测序结果均表明,miRNA-140成功克隆入pDC316-mCMV-EGFP载体中。与AdEasy重组后,包装纯化具有感染性的腺病毒miRNA-140,通过荧光定量PCR检测,软骨肉瘤细胞中miRNA-140升高4.2±0.2倍。结论:成功构建了成熟miRNA-140的腺病毒表达载体。

Objective:To construct an adenoviral vector expressing mature miRNA-140. Methods:The target Hsa-miRNA-140 gene amplified from human genome was digested and linked to the shuttle plasmid pDC316-mCMV-EGFP. The recombinant plasmid was confirmed and transfected into AAV-293 cells for adenoviruses pAd-has-miRNA-140 packaging. The obtained adenoviruses were used to infect target cells and the cellular expressions of has-miRNA-140 were detected using fluorescence and quantitative PCR. Results:Has-miRNA-140 containing the restriction sites was amplified and linked to the shuttle plasmid pDC316-mCMV-EGFP,which was successfully recombined with AdEasy.After packaging in AAV-293 cells,the adenoviruses were obtained,which caused an increase of miRNA-140 expression about 4.2±0.2 folds in osteosarcoma cells. Conclusion:The adenoviral vector expressing the mature miRNA-140 is successfully constructed.

参考文献：

[1] WAHID F,SHEHZAD A,KHAN T,et al.MicroRNAs:synthesis,mechanism,function,and recent clinical trials[J].Biochim Biophys Acta,2010,1803(11):1231-1243.
[2] FARAZI T A,HOELL J I,MOROZOV P,et al.microRNAs in Human Cancer[J].Adv Exp Med Biol,2013,774:1-20.
[3] SONG B,WANG Y,XI Y,et al.Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells[J].Oncogene,2009,28(46):4065-4074.
[4] NICOLAS F E,PAIS H,SCHWACH F,et al.Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140[J].RNA,2008,14(12):2513-2520.
[5] KOTA J,CHIVUKULA R R,O'DONNELL K A,et al.Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J].Cell,2009,137(6):1005-1017.
[6] 蒋森,赵亚萍,杜云翔.MiR-1在肿瘤中的研究进展[J].东南大学学报:医学版,2012,31(5):648-651.
[7] 蒋亮,刘春辉,许斌,等.miR-146a通过抑制ROCK1基因的表达促进去势抵抗性前列腺癌细胞的凋亡[J].东南大学学报:医学版,2015,34(3):357-360.
[8] OOM A L,HUMPHRIES B A,YANG C.MicroRNAs:novel players in cancer diagnosis and therapies[J].Biomed Res Int,2014,2014:959461.
[9] GUO X,XIA J,YAN J.Promoter methylated microRNAs:Potential therapeutic targets in gastric cancer (Review)[J].Mol Med Rep,2015,11(2):759-765.
[10] GANDELLINI P,GIOVANNETTI E,NICASSIO F.MicroRNAs in cancer management:big challenges for small molecules[J].Biomed Res Int,2015,2015:982156.
[11] EINFELD D A,ROELVINK P W.Advances towards targetable adenovirus vectors for gene therapy[J].Curr Opin Mol Ther,2002,4(5):444-451.
[12] LIU F,LI Q,ZHANG P et al.Role of adenovirus-mediated retinoblastoma 94 in the treatment of human non-small cell lung cancer[J].Mol Med Rep,2015,11(5):3349-3353.
[13] TUDDENHAM L,WHEELER G,NTOUNIA-FOUSARA S,et al.The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells[J].FEBS Lett,2006,580(17):4214-4217.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录